

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| OMB APPROVAL | |
|--|-----------|
| OMB Number: | 3235-0287 |
| Estimated average burden hours per response: | 0.5 |

| | | |
|--|--|--|
| 1. Name and Address of Reporting Person* <u>Chodakewitz Jeffrey</u> (Last) (First) (Middle) <u>C/O VERTEX PHARMACEUTICALS</u> <u>INCORPORATED</u> <u>50 NORTHERN AVENUE</u> (Street) <u>BOSTON MA 02210</u> (City) (State) (Zip) | 2. Issuer Name and Ticker or Trading Symbol <u>VERTEX PHARMACEUTICALS INC /</u> <u>MA [VRTX]</u> | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>EVP GMDA, CMO</u> |
| | 3. Date of Earliest Transaction (Month/Day/Year) <u>02/05/2018</u> | |
| | 4. If Amendment, Date of Original Filed (Month/Day/Year) | |
| 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|----------------------------|---|--|---|
| | | | Code | V | Amount | (A) or (D) | Price | | | |
| Common Stock | 02/05/2018 | | M | | 3,594 | A | \$109.14 | 56,118 | D | |
| Common Stock | 02/05/2018 | | S ⁽¹⁾ | | 494 | D | \$158.32 ⁽²⁾⁽³⁾ | 55,624 | D | |
| Common Stock | 02/05/2018 | | S ⁽¹⁾ | | 700 | D | \$159.62 ⁽³⁾⁽⁴⁾ | 54,924 | D | |
| Common Stock | 02/05/2018 | | S ⁽¹⁾ | | 500 | D | \$160.5 ⁽³⁾⁽⁵⁾ | 54,424 | D | |
| Common Stock | 02/05/2018 | | S ⁽¹⁾ | | 500 | D | \$161.51 ⁽³⁾⁽⁶⁾ | 53,924 | D | |
| Common Stock | 02/05/2018 | | S ⁽¹⁾ | | 400 | D | \$162.94 ⁽⁴⁾⁽⁷⁾ | 53,524 | D | |
| Common Stock | 02/05/2018 | | S ⁽¹⁾ | | 900 | D | \$164.12 ⁽⁴⁾⁽⁸⁾ | 52,624 | D | |
| Common Stock | 02/05/2018 | | S ⁽¹⁾ | | 100 | D | \$164.71 | 52,524 | D | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
|--|--|--------------------------------------|--|--------------------------------|---|--|-------|--|-----------------|---|--|--|---|--|-------|
| | | | | Code | V | (A) | (D) | Date Exercisable | Expiration Date | | | | | | Title |
| Stock Option (Right to Buy) | \$109.14 | 02/05/2018 | | M | | | 3,594 | (9) | 02/02/2025 | Common Stock | 3,594 | \$0.00 | 14,375 | D | |

Explanation of Responses:

- Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of \$158.32 (range \$158.01 to \$158.82).
- Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of \$159.62 (range \$159.18 to \$160.06).
- Open market sales reported on this line occurred at a weighted average price of \$160.50 (range \$160.20 to \$160.86).
- Open market sales reported on this line occurred at a weighted average price of \$161.51 (range \$161.32 to \$161.85).
- Open market sales reported on this line occurred at a weighted average price of \$162.94 (range \$162.52 to \$163.40).
- Open market sales reported on this line occurred at a weighted average price of \$164.12 (range \$163.65 to \$164.53).
- The option vests in 16 quarterly installments from 2/3/2015.

Remarks:

/s/ Omar White, Attorney-in-Fact 02/07/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.